EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management

Wael Jalloul iD, Vlad Ghizdovat iD, Tamás Pócza, Alexandra Saviuc, Despina Jalloul, Irena Cristina Grierosu, Cipriana Stefanescu

Pharmaceuticals · 18.08.2025 · 18 (8) · 1215

DOI: 10.3390/ph18081215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 18.08.2025. Verfasst von Wael Jalloul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics and Medical Physics-Nuclear Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The project SECURE (Strengthening the European Chain of sUpply for next generation medical Ra-dionuclidEs), a HORIZON EURATOM funded project, SECURE (Strengthening the European Chain of sUpply for next generation medical RadionuclidEs).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted alpha therapy (TAT) has recently emerged as a highly promising approach for the management of metastatic castration-resistant prostate cancer (mCRPC), especially in patients with disease progression despite standard treatments. Among alpha-emitter radiopharmaceuticals, actinium-225-labelled prostate-specific membrane antigen ([225Ac]Ac-PSMA) has shown remarkable potential due to its high linear energy transfer (LET), short path length, and ability to induce potent, localised cytotoxic effects. This review summarises current clinical evidence regarding [225Ac]Ac-PSMA radioligand therapy (RLT), emphasising its efficacy, safety profile, and position relative to beta-emitter therapy with lutetium-177 ([177Lu]Lu-PSMA). Data from compassionate-use programs and small clinical trials demonstrate that [225Ac]Ac-PSMA produces significant biochemical and imaging responses, including > 50% declines in prostate-specific antigen (PSA) and lesion regression on [68Ga]Ga-PSMA PET/CT, even in heavily pre-treated mCRPC cohorts. Xerostomia, renal toxicity, and haematological adverse effects remain the main safety challenges, necessitating optimisation of patient selection, dosing strategies, and salivary gland protection protocols. Compared with [177Lu]Lu-PSMA, [225Ac]Ac-PSMA appears effective even in cases of beta-refractory disease, highlighting its complementary role rather than a competitive alternative. However, limited availability, high production costs, and the lack of large-scale, randomised trials hinder widespread clinical adoption. Future directions include combination protocols, improved radiopharmaceutical design, and trials evaluating its use in earlier disease stages. This review provides a comprehensive overview of the clinical aspects of [225Ac]Ac-PSMA RLT and its evolving role in advanced prostate cancer management.

Schlagwörter

Stichwörter der Autor:innen

PSMA[68Ga]Ga-PSMA PET/CTactinium-225adverse effectslutetium-177metastatic castration-resistant prostate cancerradioligand therapytargeted alpha therapytheranostics

Autor:innen und Institutionen

  • Department of Biophysics and Medical Physics-Nuclear Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • North East Regional Innovative Cluster for Structural and Molecular Imaging (Imago-Mol), 700115 Iasi, Romania.
  • Institute of Nuclear Techniques, Budapest University of Technology and Economics, H-1111 Budapest, Hungary
  • Center of Radiotherapy, National Institute of Oncology, H-1122 Budapest, Hungary

ORCID-Profile: Wael Jalloul, Vlad Ghizdovat

Förderung

  • The project SECURE (Strengthening the European Chain of sUpply for next generation medical Ra-dionuclidEs), a HORIZON EURATOM funded project
  • SECURE (Strengthening the European Chain of sUpply for next generation medical RadionuclidEs)

Zitieren

APA

Jalloul, W., Ghizdovat, V., Pócza, T., Saviuc, A., Jalloul, D., Grierosu, I. C., & Stefanescu, C. (2025). Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management. Pharmaceuticals, 18(8), 1215. https://doi.org/10.3390/ph18081215

Vancouver

Jalloul W, Ghizdovat V, Pócza T, Saviuc A, Jalloul D, Grierosu IC, et al. Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management. Pharmaceuticals. 2025;18(8):1215. doi:10.3390/ph18081215

BibTeX
@article{Jalloul2025,
  author = {Jalloul, Wael and Ghizdovat, Vlad and Pócza, Tamás and Saviuc, Alexandra and Jalloul, Despina and Grierosu, Irena Cristina and Stefanescu, Cipriana},
  title = {Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {1215},
  doi = {10.3390/ph18081215}
}
Kostenlos starten →